title: [Effect of neoadjuvant chemotherapy on the results of resection of colorectal liver metastases].
abstract: BACKGROUND
  Surgery is the treatment of choice in patients with colorectal liver metastases. However, only 10% to 20% of these cases are resectable. The use of neoadjuvant chemotherapy may allow surgery in patients with tumors initially considered unresectable. The aim of this study was to compare the results of liver resection due to colorectal liver metastases in patients with and without neoadjuvant chemotherapy.
  
  
  METHODS
  We studied 105 patients who underwent surgery for liver metastases from colorectal cancer. The patients were divided into two groups according to treatment: surgery in patients with initially resectable tumors (group 1) and neoadjuvant chemotherapy plus surgery (group 2) in patients with initially irresectable tumors, who were considered for surgery after response to chemotherapy. Age, sex, origin of primary tumor, time of presentation, number, maximum size and location of metastases, CEA, resection margin, postoperative morbidity and mortality, length of hospital stay, recurrence rate, survival and disease-free survival were compared between the 2 groups of patients.
  
  
  RESULTS
  When group 1 was compared with group 2, statistically significant differences were observed in synchronicity (30.8% vs 77.4%), bilobarity (13.5% vs 58.5%), number and size of metastases (1 vs 3 nodules and 4 cm vs 2 cm), resectability rate (96.1% vs 81.1%), disease-free interval (25 vs 11 months) and long-term survival at 1, 3 and 5 years (93%, 67% and 36% vs 78%, 26% and 12%). However, no statistically significant differences were found in postoperative morbidity and mortality (28.8% and 0% in group 1 and 22.6% and 1.8% in group 2, respectively).
  
  
  CONCLUSIONS
  Neoadjuvant chemotherapy was not associated with greater postoperative morbidity and mortality after resection of colorectal liver metastases, but long-term survival was lower in the group of patients receiving this treatment modality than in those with tumors initially considered resectable.
authors.affiliation: Servicio de Cirugía General y Aparato Digestivo, Hospital Clínico Universitario, Valencia, España.
authors.forename: Purificación
authors.initials: P
authors.lastname: Ivorra
authors.forename: Luis
authors.initials: L
authors.lastname: Sabater
authors.forename: Julio
authors.initials: J
authors.lastname: Calvete
authors.forename: Bruno
authors.initials: B
authors.lastname: Camps
authors.forename: Andrés
authors.initials: A
authors.lastname: Cervantes
authors.forename: Ana
authors.initials: A
authors.lastname: Bosch
authors.forename: Cecilia
authors.initials: C
authors.lastname: Plazzotta
authors.forename: Norberto
authors.initials: N
authors.lastname: Cassinello
authors.forename: Patricia
authors.initials: P
authors.lastname: Arlandis
authors.forename: Salvador
authors.initials: S
authors.lastname: Lledó
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant / Q000379:methods; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome